Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04745689
Title Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

lung small cell carcinoma

Therapies

AZD2811 + Durvalumab

Cisplatin + Durvalumab + Etoposide

Carboplatin + Durvalumab + Etoposide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.